Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Our Fc Optimization platform, which introduces certain mutations into the Fc region of an antibody and modulates antibody interaction with immune effector cells, was developed with the goal of enhancing the body’s immune ability. Such interaction is believed to enhance the body’s immune ability to mediate the killing of cancer cells through antibody dependent cellular cytotoxic (ADCC).
The Fc region mediates the function of certain antibodies by binding to different activating and inhibitory IgG antibody receptors, referred to as FcγRs, on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the activating FcγRs and with a reduced affinity to the inhibitory FcγRs, improved effector functions, such as ADCC, have been seen in vitro.
We have established a proprietary platform to engineer, screen, identify and test antibodies’ Fc regions with customizable activity. To date, we have successfully incorporated our Fc variations in two of our antibody products, margetuximab which has been approved by the FDA and enoblituzumab, which is an investigational agent.